OBJECTIVE: Munich Nomenclature III for cervical smear evaluation also known as Papanicolaou (Pap) smear was launched in Germany in July 2014, and it is the only used system in Germany. The study aims at a method comparison between the previously used nomenclature Munich II and the currently used Munich III. MATERIAL AND METHODS: A method comparison was performed by analyzing 117 Pap smear samples (pss) in the cytological laboratory of the department of Obstetrics and Gynecology of Luebeck University between January and March 2014. The samples were evaluated twice using both nomenclatures (Munich II and Munich III). RESULTS: One out of the 117 pss showed a loss of cellular material. According to Munich III, this Pap smear should be linked to group 0. Concerning Pap I, Munich II showed 0/117 pss (0%) and Munich III showed 55/117 pss (47%) cases (p<0.001). Pap II results were seen less frequently in Munich III than in Munich II (47% vs 93%, p<0.001). Pap IVa, IVb, and V stay similar in both nomenclatures [IVa: 1/117 pss (0.85%), IVb: 0/117 pss (0%) and V: 1/117 pss (0.85%)]. CONCLUSION: Patients at risk are clearly separated by Munich III from those with no evidence of pathology. The former clusters have been extended by distinctly defined subgroups, resulting in a more precise way to differentiate cytological findings. Differentiating between Pap IIID 1 and IIID 2 clearly separates mild and moderate dysplasia [cervical intraepithelial neoplasia (CIN) 1 (CIN 1) and CIN 2)].
OBJECTIVE: Munich Nomenclature III for cervical smear evaluation also known as Papanicolaou (Pap) smear was launched in Germany in July 2014, and it is the only used system in Germany. The study aims at a method comparison between the previously used nomenclature Munich II and the currently used Munich III. MATERIAL AND METHODS: A method comparison was performed by analyzing 117 Pap smear samples (pss) in the cytological laboratory of the department of Obstetrics and Gynecology of Luebeck University between January and March 2014. The samples were evaluated twice using both nomenclatures (Munich II and Munich III). RESULTS: One out of the 117 pss showed a loss of cellular material. According to Munich III, this Pap smear should be linked to group 0. Concerning Pap I, Munich II showed 0/117 pss (0%) and Munich III showed 55/117 pss (47%) cases (p<0.001). Pap II results were seen less frequently in Munich III than in Munich II (47% vs 93%, p<0.001). Pap IVa, IVb, and V stay similar in both nomenclatures [IVa: 1/117 pss (0.85%), IVb: 0/117 pss (0%) and V: 1/117 pss (0.85%)]. CONCLUSION:Patients at risk are clearly separated by Munich III from those with no evidence of pathology. The former clusters have been extended by distinctly defined subgroups, resulting in a more precise way to differentiate cytological findings. Differentiating between Pap IIID 1 and IIID 2 clearly separates mild and moderate dysplasia [cervical intraepithelial neoplasia (CIN) 1 (CIN 1) and CIN 2)].
Entities:
Keywords:
Munich nomenclature II; Munich nomenclature III; Pap smear
Authors: G Kocjan; B C Priollet; M Desai; H Koutselini; V Mahovlic; M H Oliveira; Z Pohar-Marinsek; T Sauer; U Schenk; I Shabalova; A Herbert Journal: Cytopathology Date: 2005-06 Impact factor: 2.073
Authors: Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young Journal: JAMA Date: 2002-04-24 Impact factor: 56.272
Authors: M Arbyn; A Anttila; J Jordan; G Ronco; U Schenck; N Segnan; H Wiener; A Herbert; L von Karsa Journal: Ann Oncol Date: 2010-03 Impact factor: 32.976
Authors: Frederik A Stuebs; Martin C Koch; Anna K Dietl; Werner Adler; Carol Geppert; Arndt Hartmann; Antje Knöll; Matthias W Beckmann; Grit Mehlhorn; Carla E Schulmeyer; Paul Gass Journal: Diagnostics (Basel) Date: 2022-07-19
Authors: Wegene Borena; Margarethe Grünberger; Andreas Widschwendter; Karl Heinz Kraxner; Elisabeth Marth; Peter Mayr; Joerg Meier; Norman Ruth; Aida Tort Guerrero; Christian Marth; Dorothee Holm-von Laer Journal: BMC Public Health Date: 2016-08-26 Impact factor: 3.295